Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 6
2009 18
2010 33
2011 49
2012 70
2013 70
2014 88
2015 96
2016 84
2017 114
2018 133
2019 103
2020 15
Text availability
Article attribute
Article type
Publication date

Search Results

732 results
Results by year
Filters applied: . Clear all
Page 1
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Krueger G. Papp K, et al. J Drugs Dermatol. 2015 Jul;14(7):706-14. J Drugs Dermatol. 2015. PMID: 26151787
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.
Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, Ramachandran P, Ott E, Strober BE. Ghosh S, et al. Drug Saf. 2019 Jun;42(6):751-768. doi: 10.1007/s40264-019-00797-3. Drug Saf. 2019. PMID: 30739254 Free PMC article. Clinical Trial.
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C. Duarte A, et al. Health Technol Assess. 2017 Nov;21(64):1-244. doi: 10.3310/hta21640. Health Technol Assess. 2017. PMID: 29105621 Free PMC article. Review.
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ. Papp KA, et al. N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017. N Engl J Med. 2017. PMID: 28423301 Free article. Clinical Trial.
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A. Lebwohl M, et al. N Engl J Med. 2015 Oct;373(14):1318-28. doi: 10.1056/NEJMoa1503824. N Engl J Med. 2015. PMID: 26422722 Free article. Clinical Trial.
Ustekinumab for the treatment of psoriasis: an evidence update.
Yiu ZZ, Warren RB. Yiu ZZ, et al. Semin Cutan Med Surg. 2018 Sep;37(3):143-147. doi: 10.12788/j.sder.2018.040. Semin Cutan Med Surg. 2018. PMID: 30215630 Review.
Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
Deepak P, Sandborn WJ. Deepak P, et al. Gastroenterol Clin North Am. 2017 Sep;46(3):603-626. doi: 10.1016/j.gtc.2017.05.013. Gastroenterol Clin North Am. 2017. PMID: 28838418 Review.
732 results
Jump to page
Feedback